Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA ISOTOPE & RADIATION CORPORATION
中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

INSIDE INFORMATION
POTENTIAL CAPITAL INCREASE OF CNGT THROUGH PUBLIC TENDER

This announcement is made by China Isotope & Radiation Corporation (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of the Hong Kong).

POTENTIAL CAPITAL INCREASE OF CNGT THROUGH PUBLIC TENDER

The board of directors (the "**Board**") of the Company announces that, Chengdu Zhonghe High-Tech Isotope Co., Ltd (成都中核高通同位素股份有限公司) ("**CNGT**"), the Company's non-wholly-owned subsidiary, intends to conduct a capital increase (the "**Potential Capital Increase**") through a public tender process on China Beijing Equity Exchange (北京產權交易所) ("**CBEX**"). In compliance with the relevant regulatory requirements of the PRC, a preliminary disclosure of information in relation to the Potential Capital Increase (the "**Preliminary Disclosure**") has also been made to the public on the website of CBEX on the date of this announcement.

The consideration of the Potential Capital Increase will be determined based on the appraisal value of CNGT as conducted by a reputable valuer.

REASONS FOR AND BENEFITS OF THE POTENTIAL CAPITAL INCREASE

As of 31 December 2024, CNGT's gearing ratio was 68.85%. To address its funding needs for development and optimize its capital structure, CNGT proposes to alleviate its financial pressure through the Potential Capital Increase, thereby supporting its core business expansion and operational capability enhancement. The Board believes that such capital increase will not only ensure CNGT's sustainable development but also comply with the Group's overall financial control requirements, which will help enhance the Group's overall asset quality and risk resilience.

INFORMATION ON CNGT

CNGT is a non-wholly-owned subsidiary of the Company, which is principally engaged in the development, production and sales of radioactive isotope products, while also conducting import-export trade and cargo transportation. As of the date of this announcement, each of the Company, Sichuan Qingyi Development Investment Group Co., Ltd. (四川青衣開發投資集團有限公司), MASEP Medical Science & Technology Development (Shenzhen) Co., Ltd. (瑪西普醫學科技發展(深圳)有限公司) and Nuclear Power Institute of China (中國核動力研究設計院) holds 93.1533%, 3.2586%, 3.0922% and 0.4959% equity interest in CNGT, respectively.

As of 31 December 2024, CNGT's total assets amounted to RMB1,456.22 million, with a revenue of RMB618 million and a net profit of RMB63.66 million.

GENERAL

The Preliminary Disclosure is only for information disclosure in advance, and does not constitute a transaction under Chapter 14 or Chapter 14A of the Listing Rules. The Potential Capital Increase, if materialized, may constitute a discloseable transaction or connected transaction of the Company. The Company will make further announcement with respect to any major update and progress of the Potential Capital Increase as and when appropriate in compliance with applicable legal and regulatory requirements.

Shareholders and potential investors of the Company should note that as the Potential Capital Increase is only at the Preliminary Disclosure stage, the Potential Capital Increase may or may not materialize. Shareholders and potential investors of the Company should be aware that there is no assurance that the Potential Capital Increase will materialize or as to when it may materialize. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the share(s) of the Company.

By order of the Board
China Isotope & Radiation Corporation
Chairman
Xiao Yafei

Beijing, the PRC, 31 July 2025

As at the date of this announcement, the Board comprises Mr. Xiao Yafei, Mr. Zhang Junqi, Ms. Huo Yingying and Ms. Ma Xiaoyu as executive Directors; Mr. Chen Zan, Mr. Ding Jianmin and Ms. Chang Jinyu as non-executive Directors; and Mr. Poon Chiu Kwok, Ms. Chen Jingshan, Mr. Lu Chuang and Mr. An Rui as independent non-executive Directors.